| Literature DB >> 27538431 |
Hao Wu1, Fan Jiang1, Haizhen Yue1, Hui Zhang2, Kun Wang2, Yibao Zhang3.
Abstract
BACKGROUND: The development of a dose-volume-histogram (DVH) estimation model for knowledge-based planning is very time-consuming and it could be inefficient if it was only used for similar upcoming cases as supposed. It is clinically desirable to explore and validate other potential applications for a configured model. This study tests the hypothesis that a supine volumetric modulated arc therapy (VMAT) model can optimize intensity modulated radiotherapy (IMRT) plans of other patient setup orientations.Entities:
Keywords: IMRT; Knowledge-based planning; Model application; RapidPlan; Setup orientation; VMAT
Mesh:
Year: 2016 PMID: 27538431 PMCID: PMC4990878 DOI: 10.1186/s13014-016-0684-9
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Validation of DVH estimation model by applying it to similar cases: dosimetric comparison between the 10 clinical supine VMAT plans and their knowledge-based re-optimizations
| Mean | SD | 95 % Confidence intervals | △(%) |
| |||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| HI_PGTV | Original | 0.06 | 0.01 | 0.05 | 0.07 | 0.01 | 0.15* |
| RP-VMAT | 0.05 | 0.01 | 0.05 | 0.06 | |||
| HI_PTV | Original | 0.26 | 0.01 | 0.25 | 0.27 | 0 | 0.62* |
| RP-VMAT | 0.26 | 0.01 | 0.25 | 0.27 | |||
| CI_PGTV | Original | 1.01 | 0.04 | 0.98 | 1.04 | 0.01 | 0.11 |
| RP-VMAT | 1.00 | 0.04 | 0.97 | 1.03 | |||
| CI_PTV | Original | 1.03 | 0.02 | 1.02 | 1.05 | 0.01 | 0.05* |
| RP-VMAT | 1.02 | 0.02 | 1.01 | 1.04 | |||
| Dmax | Original | 53.93 | 0.35 | 53.69 | 54.18 | 0.36 (0.67 %) | 0.07* |
| RP-VMAT | 53.57 | 0.50 | 53.22 | 53.93 | |||
| D2 % | Original | 53.37 | 0.37 | 53.10 | 53.63 | 0.34 (0.64 %) | 0.15* |
| RP-VMAT | 53.03 | 0.46 | 52.70 | 53.36 | |||
| D50 %_UB | Original | 28.90 | 5.31 | 25.10 | 32.69 | 5.39 (18.65 %) | 0.01 |
| RP-VMAT | 23.51 | 3.26 | 21.18 | 25.84 | |||
| D50 %_FH | Original | 16.30 | 1.66 | 15.11 | 17.48 | 2.30 (14.11 %) | 0.01 |
| RP-VMAT | 14.00 | 0.92 | 13.34 | 14.65 | |||
| Dmean_UB | Original | 30.01 | 4.52 | 26.77 | 33.24 | 4.51 (15.03 %) | 0.01 |
| RP-VMAT | 25.50 | 1.54 | 24.40 | 26.60 | |||
| Dmean_FH | Original | 17.18 | 1.80 | 15.90 | 18.47 | 1.85 (10.77 %) | 0.01 |
| RP-VMAT | 15.33 | 0.68 | 14.85 | 15.82 | |||
| MUs | Original | 412 | 41 | 383 | 441 | 18 (4.37 %) | 0.14 |
| RP-VMAT | 430 | 23 | 413 | 447 | |||
Abbreviations: HI homogeneity index, CI conformity index, D global maximum dose, D near maximum dose, SD standard deviation, △(%) difference between the original and RP-VMAT plans (% relative to the original value), D dose to the 50 % volume of the structure, D mean dose, FH femoral head, UB urinary bladder, MU monitor unit, RP-VMAT volumetric modulated arc therapy plans optimized by RapidPlan. Dose unit (Gy)
*Paired sample T test, otherwise Wilcoxon signed ranks test was used
Fig. 1Mean DVHs of 30 IMRT patients planned by experience-based (original) or knowledge-based (RapidPlan) methods regardless of the setup orientations
Dosimetric comparison between the clinical IMRT plans (of both supine and prone setups) and their knowledge-based re-optimization using the DVH estimation model trained on supine VMAT plans
| Mean | SD | 95 % Confidence intervals | △(%) |
| |||
|---|---|---|---|---|---|---|---|
| Lower | Upper | ||||||
| HI_PGTV | Original | 0.04 | 0.01 | 0.04 | 0.05 | 0.01 | 0.04 |
| RP-IMRT | 0.05 | 0.01 | 0.04 | 0.05 | |||
| HI_PTV | Original | 0.25 | 0.01 | 0.24 | 0.25 | 0.01 | 0.01* |
| RP-IMRT | 0.26 | 0.01 | 0.25 | 0.26 | |||
| CI_PGTV | Original | 1.03 | 0.05 | 1.01 | 1.05 | 0.01 | 0.61 |
| RP-IMRT | 1.02 | 0.05 | 1.00 | 1.04 | |||
| CI_PTV | Original | 1.01 | 0.02 | 1.00 | 1.02 | 0.17 | <0.01* |
| RP-IMRT | 1.18 | 0.05 | 1.16 | 1.20 | |||
| Dmax | Original | 52.95 | 0.44 | 52.78 | 53.11 | 1.51 (2.85 %) | <0.01 |
| RP-IMRT | 54.46 | 1.52 | 53.89 | 55.02 | |||
| D2 % | Original | 52.61 | 0.43 | 52.44 | 52.77 | 0.15 (0.29 %) | 0.09 |
| RP-IMRT | 52.76 | 0.51 | 52.57 | 52.95 | |||
| D50 %_UB | Original | 33.85 | 2.96 | 32.74 | 34.95 | 8.76 (25.88 %) | <0.01* |
| RP-IMRT | 25.09 | 1.32 | 24.59 | 25.58 | |||
| D50 %_FH | Original | 15.65 | 3.33 | 14.41 | 16.90 | 1.92 (12.27 %) | <0.01* |
| RP-IMRT | 13.73 | 1.43 | 13.19 | 14.26 | |||
| Dmean_UB | Original | 33.99 | 2.77 | 32.95 | 35.02 | 7.74 (22.77 %) | <0.01 |
| RP-IMRT | 26.25 | 1.22 | 25.79 | 26.70 | |||
| Dmean_FH | Original | 16.26 | 2.74 | 15.24 | 17.28 | 1.64 (10.09) | <0.01 |
| RP-IMRT | 14.62 | 1.10 | 14.21 | 15.04 | |||
| MUs | Original | 805 | 82 | 774 | 836 | 394 (48.94 %) | <0.01* |
| RP-IMRT | 1199 | 80 | 1169 | 1229 | |||
Abbreviations: HI homogeneity index, CI conformity index, D global maximum dose, D near maximum dose, SD standard deviation, △(%) difference between the original and RP-VMAT plans (% relative to the original value), D dose to the 50 % volume of the structure, D mean dose, FH femoral head, UB urinary bladder, MU monitor unit, RP-IMRT intensity modulated radiotherapy plans optimized by RapidPlan. Dose unit (Gy)
*Paired sample T test, otherwise Wilcoxon signed ranks test was used
Dosimetric statistics between the supine and prone IMRT patients
| Original | RapidPlan | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | 95 % CIs | △(%) |
| Mean | SD | 95 % CIs | △(%) |
| ||
| HI_PGTV | S. | 0.04 | 0.01 | 0.04 ~ 0.05 | 0 | 0.66* | 0.05 | 0.01 | 0.04 ~ 0.05 | 0 | 0.97 |
| P. | 0.04 | 0.01 | 0.04 ~ 0.05 | 0.05 | 0.01 | 0.04 ~ 0.06 | |||||
| HI_PTV | S. | 0.24 | 0.01 | 0.24 ~ 0.25 | 0.01 | 0.24* | 0.25 | 0.01 | 0.25 ~ 0.26 | 0.01 | 0.22* |
| P. | 0.25 | 0.01 | 0.24 ~ 0.25 | 0.26 | 0.02 | 0.25 ~ 0.26 | |||||
| CI_PGTV | S. | 1.03 | 0.07 | 0.99 ~ 1.09 | 0.01 | 0.73 | 1.01 | 0.06 | 0.97 ~ 1.05 | 0.01 | 0.48 |
| P. | 1.02 | 0.05 | 1.00 ~ 1.04 | 1.02 | 0.05 | 0.99 ~ 1.04 | |||||
| CI_PTV | S. | 1.02 | 0.02 | 1.00 ~ 1.04 | 0.01 | 0.16 | 1.19 | 0.07 | 1.14 ~ 1.24 | 0.01 | 0.56* |
| P. | 1.01 | 0.02 | 1.00 ~ 1.02 | 1.18 | 0.05 | 1.16 ~ 1.20 | |||||
| Dmax | S. | 52.93 | 0.45 | 52.61 ~ 53.25 | 0.03 (0.06 %) | 0.98 | 54.73 | 1.67 | 53.53 ~ 55.93 | 0.41 (0.75 %) | 0.48 |
| P. | 52.96 | 0.45 | 52.75 ~ 53.17 | 54.32 | 1.46 | 53.64 ~ 55.00 | |||||
| D2 % | S. | 52.56 | 0.41 | 52.26 ~ 52.85 | 0.07 (0.13 %) | 0.68* | 52.71 | 0.24 | 52.53 ~ 52.88 | 0.08 (0.15 %) | 0.86 |
| P. | 52.63 | 0.45 | 52.42 ~ 52.84 | 52.79 | 0.61 | 52.50 ~ 53.07 | |||||
| D50 %_UB | S. | 34.13 | 2.73 | 32.16 ~ 36.06 | 0.41 (1.20 %) | 0.74* | 25.12 | 0.84 | 24.52 ~ 25.72 | 0.05 (0.20 %) | 0.93* |
| P. | 33.72 | 3.12 | 32.26 ~ 35.18 | 25.07 | 1.53 | 24.36 ~ 25.79 | |||||
| D50 %_FH | S. | 18.89 | 2.69 | 16.96 ~ 20.81 | 4.85 (25.67 %) | <0.01* | 14.67 | 1.80 | 13.38 ~ 15.95 | 1.41 (9.61 %) | 0.01* |
| P. | 14.04 | 2.28 | 12.97 ~ 15.11 | 13.26 | 0.94 | 12.82 ~ 13.70 | |||||
| Dmean_UB | S. | 34.25 | 2.90 | 32.17 ~ 36.32 | 0.39 (1.14 %) | 0.72* | 26.19 | 0.97 | 25.50 ~ 26.89 | 0.08 (0.31 %) | 0.87* |
| P. | 33.86 | 2.77 | 32.56 ~ 35.15 | 26.27 | 1.36 | 25.64 ~ 26.91 | |||||
| Dmean_FH | S. | 19.23 | 2.41 | 17.51 ~ 20.96 | 4.45 (23.14 %) | <0.01 | 15.41 | 1.07 | 14.64 ~ 16.17 | 1.18 (7.66 %) | <0.01* |
| P. | 14.78 | 1.31 | 14.17 ~ 15.39 | 14.23 | 0.91 | 13.81 ~ 14.66 | |||||
Abbreviations: S. supine, P. prone, HI homogeneity index, CI conformity index, △(%) difference between the supine and prone plans (% relative to the supine value), D global maximum dose, D near maximum dose, SD standard deviation, 95 % CI 95 % confidence interval, D dose to the 50 % volume of the structure, D mean dose, FH femoral head, UB urinary bladder. Dose unit (Gy)
*Independent sample t-test, otherwise Mann-Whitney U test was used